Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prevention study of Lian-Hua Qing-Wen Capsules in close contacts of COVID-19 cases
ChiCTR2100043012Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Feb 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of Lianhua Qingwen in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The Second Hospital of Hebei Medical University. Primary endpoint: Positive rate of nasal and throat swab nucleic acid tests during quarantine medical observation. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
Lianhua Qingwen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100043012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043012.